Introduction
Anthem Biosciences Ltd., a contract research, development, and manufacturing company, has made headlines recently with its initial public offering (IPO) being subscribed 63.86 times on its final day. The issue, which was open for subscription from July 14 to July 16, received an overwhelming response from investors, with non-institutional investors leading the charge.
